FCM
PBYI icon

Farallon Capital Management’s Puma Biotechnology PBYI Stock Holding History

Farallon Capital Management’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-410,000
Closed -$18.8M – 101
2018
Q3 		$18.8M Buy
+410,000
New +$19.8M 0.11% 70
2017
Q3 		– Sell
-213,000
Closed -$18.6M – 91
2017
Q2 		$18.6M Sell
213,000
-367,500
-63% -$20.6M 0.19% 56
2017
Q1 		$21.6M Buy
+580,500
New +$21.2M 0.24% 53

Other funds holding PBYI

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Farallon Capital Management's PBYI Position: Q4 2018 in Review

Farallon Capital Management sold out of Puma Biotechnology (PBYI) in Q4 2018, closing a stake of 410,000 shares — an estimated $18.8M sold.

Farallon Capital Management first reported a position in PBYI in Q1 2017 and held it in 3 quarters. The position peaked at $21.6M in Q1 2017. 141 funds tracked by Wall St. Rank hold PBYI as of Q4 2018.

  • Farallon Capital Management reported no remaining Puma Biotechnology position as of Q4 2018 after selling out during the quarter.
  • Farallon Capital Management sold 410,000 Puma Biotechnology shares in Q4 2018, an estimated $18.8M.
  • Farallon Capital Management first reported a position in Puma Biotechnology in Q1 2017 and held it in 3 quarters.
  • Farallon Capital Management's Puma Biotechnology position peaked at $21.6M in Q1 2017.
  • 141 funds tracked by Wall St. Rank held Puma Biotechnology as of Q4 2018.

Based on Farallon Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.